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Abstract
Genetically modified rhesus macaques are necessary because mouse models are not suitable for a
number of important neurogenetic disorders; for example, Kallmann's syndrome, Lesch-Nyhan's
disease and Ataxia-Telangiectasia. Mouse models may not be suitable because there may be no
mouse ortholog of the human gene of interest, as is the case for Kallmann's syndrome, or because
mutant mice do not exhibit the same phenotype observed in humans, as is the the case for Lesch-
Nyhan's disease and Ataxia-Telangiectasia. Non-human primate models of neurogenetic diseases
are expected to more closely resemble human diseases than existing mouse models. Genetically
modified rhesus macaques can be created by modifying the genome of a somatic cell and then
transferring the nucleus from this cell to an enucleated oocyte. Random integration of a transgene
is sufficient to create models of gain-of-function genetic diseases. Stable expression of green
fluorescent protein has been achieved in rhesus macaque fibroblasts. However, gene targeting is
necessary to create models of loss-of-function genetic diseases. Several technical challenges must
be overcome before null mutant non-human primates can be produced. In our experience, fetal
fibroblasts frequently become senescent before selection procedures can be completed. We have
overcome this problem by transfecting somatic cells with human telomerase reverse transcriptase.
This enzyme extends the telomeres, and lifespan, of somatic cells. Long and accurate polymerase
chain reaction can be used to obtain sufficient regions of homology of isogenic rhesus genomic
DNA for targeting constructs. This should improve gene targeting efficiency. Gene targeting
experiments are currently underway. Null mutant rhesus macaques will likely result in
breakthrough advances in the understanding of neurogenetic disease and prove invaluable for
preclinical trials of new therapies.
Review – The need for non-human primate 
models for neurogenetic diseases
Although genetically modified mice have provided
important new information about the function of many
genes, there are serious limitations to current animal
models for a number of neurogenetic diseases. One rea-
son for this is that a mouse ortholog to a human gene of
interest may not exist. It is estimated that between 0.5 –
1% of human genes do not have mouse orthologs [1]. For
example, no mouse ortholog has been identified for the
KAL1 gene. Loss-of-function mutations in this gene cause
Kallmann's syndrome, a neurodevelopmental disorder
that results in anosmia and hypothalamic hypogonadism
[2-5]. KAL1 is located in close proximity to pseudoauto-
somal region 1 (PAR1) and escapes X-inactivation [3,6-9].
Rearrangements in this region during rodent evolution
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may be the reason a mouse ortholog of KAL1 cannot be
found [10,11].
While mouse orthologs to genes involved in human dis-
eases can usually be found, targeted mutations of these
genes in mice may not result in any of the symptoms
observed in humans with loss-of-function mutations in
these genes. For example, the HPRT1 gene is mutated in
Lesch-Nyhan's disease [12,13]. Symptoms include mental
retardation, self-mutilation, choreoathetosis and spastic-
ity. HPRT1 mutant mice do not exhibit the Lesch-Nyhan's
disease phenotype [14]. It is interesting to note that
HPRT1 was the first gene to be disrupted in mice [15,16].
The most common problem with gene targeted mice is
that they sometimes provide incomplete models of the
human phenotype. For example, children with Ataxia-Tel-
angiectasia (due to mutations in the ATM gene) exhibit
ataxia (due to neurodegeneration of the Purkinje cells of
the cerebellum), increased incidence of cancer and
immune system dysfunction [17-20]. Mice with muta-
tions in the ATM gene exhibit increased incidence of can-
cer and immune system dysfunction, but not
degeneration of the Purkinje neurons and ataxia [21-23].
Mouse models of Alzheimer's disease also exhibit some
but not all of the symptoms of this disease [24-26].
Rhesus macaque models of neurogenetic diseases are par-
ticularly desirable because the organization of the rhesus
brain more closely resembles the human brain than does
any non-primate brain. Monkey brains greatly exceed the
size and complexity observed in mouse brains. As a con-
sequence, rhesus macaques exhibit perceptual, cognitive
and behavioral plasticity not observed in mice [27-29].
Neurological disorders may require novel therapeutic
methods, such as gene therapy, which contain significant
risks [30-32]. The availability of non-human primate
(NHP) models will be essential to guarantee safety and
efficacy of these new treatment options.
A new approach to genetic modification in 
mammals
The key to successful gene targeting in mice has been the
availability of embryonic stem (ES) cells [15,33-39].
These cells have two important characteristics which facil-
itate genetic modification: 1. They are immortal and can
therefore be propagated indefinitely in cell culture, and 2.
They are totipotent and can therefore be used to create chi-
meric animals [38-40]. Some of these chimeric animals
will contain germ cells derived from genetically modified
ES cells. Breeding of chimeric animals can thus result in
offspring in which every cell is genetically modified.
Although ES cells have been derived in several mamma-
lian species (including rhesus macaques), such cells have
not yet been used to create gene-targeted animals [41-47].
Murine ES cells appear to have especially favorable char-
acteristics for gene targeting. The lack of ES cells with the
same favorable attributes has limited progress in develop-
ing non-murine mammalian genetic models of human
disease. However, even if such cells were available, the
requirement that chimeric animals be bred to produce
animals with the genetic modification in all cells would
mean that it would take at least 5 years to produce a het-
erozygote (since macaques do not breed until they are 4–
5 years old) [48]. Breeding to produce homozygotes
would require at least 10 years.
The recent development of nuclear transfer techniques to
create animals (whole animal cloning) has made it possi-
ble to perform gene targeting in mammals other than
mice (sheep and pigs) [49-54]. The basic idea is to per-
form gene targeting in somatic cells and to then transfer
the nuclei of these genetically modified cells to enucleated
oocytes. The resulting embryos are then transferred to a
surrogate mother. The animal that develops from this
embryo should contain the genetic modification in every
cell of its body. Application of this approach to rhesus
macaques could be used to create NHP models of neuro-
genetic disease.
Gene/disease selection
Given the difficulty associated with generating a gene-tar-
geted rhesus macaque, it is important to have a set of cri-
teria for disease/gene selection. Our criteria are as follows:
1. Mutation in the gene should cause a serious human dis-
ease 2. No complete mouse model should be available 3.
The phenotype should be apparent early in the lifespan of
rhesus macaque. We are currently working on three genes/
diseases that meet these criteria: HPRT1/Lesch-Nyhan's
disease, KAL1/ Kallmann's syndrome and ATM/ataxia
telangiectasia.
Lesch-Nyhan's disease is a neurodevelopmental disorder
that is caused by loss-of-function mutations in the HPRT1
gene [12]. HPRT1 is located on chromosome X. As a
result, most individuals affected by this disease are males.
The HPRT1 gene encodes hypoxanthine guanine phos-
phoribosyltransferase, an enzyme involved in purine
metabolism. The link between loss of this enzyme and the
mental retardation and self-injurious behavior observed
in patients with Lesch-Nyhan's disease is currently not
understood. The absence of any similar deficits in HPRT1
null mutant mice has hindered understanding and treat-
ment of this disease [14].
Loss-of-function mutations in KAL1, located on chromo-
some X, cause some forms of Kallmann's syndrome [3,4].
In patients with Kallmann's syndrome, the olfactory nerve
is formed but does not enter the telencephalon, resultingReproductive Biology and Endocrinology 2004, 2:40 http://www.rbej.com/content/2/1/40
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in anosmia. Because gonadotropin releasing hormone
(GnRH) neurons originate in the olfactory placode and
migrate to the brain early in embryonic development with
the olfactory nerve, GnRH neurons form, but do not enter
the brain in Kallmann's syndrome patients [2]. As a result,
these individuals do not undergo puberty. One hypothe-
sis regarding KAL1 function is that it helps guide olfactory
nerve axons, and the GnRH neurons associated with
them, into the brain [55]. However, the absence of a
mouse ortholog to human KAL1 makes interpretation of
available studies problematical.
Ataxia-telangiectasia is a neurodegenerative disease that is
initially observed in young children [56,57]. Loss-of-func-
tion mutations in ATM, located on chromosome 11, cause
this disease [20]. ATM is a key player in responding to
DNA double-strand breaks [18]. Patients with ATM are at
increased risk of cancer. Although ATM null mutant mice
have been helpful in understanding the role of ATM in
cancer, the failure of these animals to exhibit the loss of
Purkinje cells of the cerebellum seen in patients has hin-
dered an understanding of how mutations in ATM result
in neurodegeneration. Perhaps as a result, little progress
has been made in treating the neurological symptoms of
this disease [58].
Random integration of transgenes
Some neurogenetic diseases are due to gain-of-function
mutations. Random integration of a deleterious transgene
into the rhesus genome would be sufficient to create effec-
tive animal models for these types of disease. Examples of
gain-of-function mutations include CAG trinucleotide
repeat disorders, such as Huntington's disease and spinal
cerebellar ataxia 3. In these diseases, the trinucleotide
CAG (which codes for gluatmine) is repeated to a greater
extent than in unaffected individuals. The long stretches
of polyglutamine observed in the relevant proteins are
thought to be toxic to neurons [59]. Some forms of Alzhe-
imer's disease and Parkinson's disease are also due to
gain-of-function mutations [60,61]. However, many gain-
of-function neurodegenerative diseases take decades to
develop in humans, and would probably take many years
to develop in rhesus macaque genetic models.
Random integration of transgenes to create transgenic ani-
mals may be accomplished in several ways. One approach
is to introduce the transgene into germ cells followed by
fertilization. Rhesus macaque sperm were mixed with a
plasmid containing a green fluorescent protein (GFP)
reporter construct and injected into oocytes [62]. The
developing embryos expressed GFP but the one healthy
newborn did not [62]. A retroviral vector has been used to
introduce a GFP expression cassette into a rhesus macaque
oocyte which was subsequently fertilized in vitro [63]. RT-
PCR indicated that the animal expressed GFP mRNA; GFP
protein was not observed [63].
Transgenes can also be introduced randomly into early
embryos. Lentiviral infection of rhesus blastocysts has
been used to introduce a GFP expression vector [64]. GFP
expression was observed in the placenta, but not in the
somatic tissues of the newborns [64]. An Epstein-Barr
virus-based episomal vector has been injected into the
pronuclei of rhesus embryos [65]. Blastocyst-stage
embryos were shown to express GFP with this technique
[65].
One disadvantage of introducing transgenes into germ
cells or early embryos is that selection for stable expres-
sion of the transgene is not possible. Another approach is
to introduce transgenes into somatic cells, select for stable
expression of the transgene, and then transfer the nuclei of
such cells to enucleated oocytes. We have observed stable
expression of GFP in rhesus fibroblasts after transfection
with a reporter construct. Such cells could be used to cre-
ate transgenic macaques using nuclear transfer.
Gene targeting in rhesus macaque fibroblasts – 
problems and solutions
Although random integration of a transgene into the rhe-
sus genome would be useful for creating models for a
small number of diseases, many neurological disorders
are due to loss-of-function mutations. Examples include
Kallmann's syndrome, some forms of mental retardation
(e. g. Lesch-Nyhan's disease), ataxia (e. g. Ataxia-Tel-
angiectasia), deafness, blindness and some forms of Par-
kinson's disease [3,4,12,13,18,19,66-69]. Gene targeting
will be necessary to create animal models for these dis-
eases. Gene targeting is much more difficult to achieve
than random integration of constructs.
There are four major barriers to gene targeting in somatic
cells: Senescence, lack of isogenic DNA libraries, the
impracticality of crosses to get homozygotes, and ineffi-
cient gene targeting.
Somatic cells, unlike ES cells, are mortal [70,71]. This is a
problem for gene targeting as the necessary steps (trans-
fection, selection and screening) require a significant
number of population doublings [54,72]. In our experi-
ence, rhesus fibroblasts frequently become senescent dur-
ing the time in vitro required for gene targeting. One
solution to this problem is the use of human telomerase
reverse transcriptase (hTERT). hTERT reverse transcribes
telomerase RNA (TR) to extend telomeres [73-75]. The
erosion of telomeres during cell division causes senes-
cence in some cell types [75-77]. TERT expression is the
rate limiting step in telomere extension [73]. TERT expres-
sion has been shown to immortalize fibroblasts, retinalReproductive Biology and Endocrinology 2004, 2:40 http://www.rbej.com/content/2/1/40
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pigmented epithelial cells, endothelial cells, keratinoc-
ytes, mammary epithelial cells and osteoblasts [78-85].
Importantly, transfection of hTERT constructs has been
shown to extend the lifespan of rhesus fibroblasts indefi-
nitely [86,87]. Further, although there are other methods
for immortalizing cells, only TERT immortalizes without
transforming cells [81,85,88,89]. This is important for our
approach as an entire animal will be generated from the
nucleus of the cell transferred to the enucleated oocyte.
The unique properties of TERT make it an ideal reagent for
extending the lifespan of fibroblasts to permit gene-target-
ing. However, constitutive TERT expression may alter gene
expression in somatic cells [90]. Because the phenotypic
effects of constitutive TERT expression in a primate are
unknown, it is important that construct-derived TERT
only be expressed in cell culture. Constitutive TERT
expression in sheep embryos created by nuclear transfer
did not interfere with blastocyst formation, implantation
or early embryonic development but may have interfered
with fetal development [91]. To avoid deleterious effects
of constitutive expression of TERT on fetal development,
construct-derived TERT could be removed with the Cre-
lox system prior to nuclear transfer. Alternatively, TERT
could be expressed in cell culture, during selection and
screening procedures, under the control of an inducible
promoter.
There is general agreement that the use of isogenic DNA in
gene targeting vectors improves targeting efficiency
[92,93] (although see [94] for a different opinion). For
inbred strains of mice, acquiring isogenic genomic DNA is
quite easy as genomic BAC libraries from the same strain
used to create null mutants is available. Recently, a rhesus
BAC genomic library has been constructed by Pieter de
Jong and colleagues http://bacpac.chori.org/
rhesus250.htm. However, during the development of null
mutant rhesus macaque technology, different cell types
derived from different animals will be investigated for
efficiency of gene-targeting and nuclear transfer. It is
impractical to create a BAC library for each animal used.
Thus, another method must be used to acquire homolo-
gous genomic sequence. The use of long and accurate PCR
provides a solution to this problem. Primers can be
designed that will consistently amplify genomic frag-
ments sufficiently long to create targeting vectors. A PCR-
based approach provides considerable flexibility as
homologous DNA can rapidly be obtained from cells of
different animals facilitating the construction of new, iso-
genic targeting vectors.
Homozygotes are required to observe a phenotype for
many loss-of-function diseases. However, rhesus
macaques do not breed until they are 4–5 years old [48].
Thus, producing homozygotes would take a minimum of
5 years using breeding. One way to avoid this wait is to
target X-linked recessive genes in XY cells. In this case, it
will only be necessary to disrupt one allele to see a pheno-
type. For autosomal recessive genes, it will still be neces-
sary to disrupt two copies of a gene. This can be
accomplished by successive rounds of gene targeting [95].
The use of TERT-lifespan-extended cells makes this
approach practical.
Gene targeting is very inefficient in comparison with ran-
dom integration of constructs, even in mouse embryonic
stem cells. How efficient is gene targeting in rhesus fibrob-
lasts likely to be? Since gene targeting has been achieved
in fibroblasts for several species, including humans, it is
instructive to consider rates of success in these species. The
first report of gene targeting in fibroblasts followed by
nuclear transfer occurred in sheep [53]. A very high level
of gene targeting efficiency was observed using Lipo-
fectamine for transfection [53]. In contrast, low levels of
gene targeting efficiency were observed in sheep, pig and
human fibroblasts using electroporation for transfection
[50,51,54,96]. The reported high efficiency of gene target-
ing with Lipofectamine in sheep fibroblasts is surprising
given that chemical methods have been shown to be a
poor method for gene targeting both in mouse and
human ES cells [97,98]. For this reason, electroporation is
the gene targeting method of choice for ES cells [97,98].
Our preliminary results suggest that the high levels of suc-
cess obtained in sheep fibroblasts with Lipofectamine are
unlikely to be obtained with rhesus fibroblasts. Our
expectation is that electroporation will be necessary to
achieve gene targeting, but that efficiency is likely to be
quite low [72].
Given an expected low efficiency of gene targeting, it is
important to design experiments to maximize chances of
success. For example, it is expected that large numbers of
cells will be required. Fortunately, TERT life span exten-
sion means that unlimited numbers of cells are available
for experimentation. The length of homology is another
variable which may influence success in gene targeting
[15,99]. We have been able to obtain homologous
sequence of at least 9 kb for each of the three genes we
plan to disrupt. This should be a sufficient length of
homology to construct good targeting vectors. Because
gene targeting is an infrequent event in comparison to
random integration of the targeting construct, enrichment
for targeting events is desirable. This can be achieved
through the use of promoterless neomycin resistance cas-
settes [100,101]. With these constructs, expression of neo-
mycin resistance is contingent upon integration within a
gene. Since the genic region only constitutes 3% of the
genome, most random integrants will be selected against.
All genetically modified animals created from the transfer
of the nucleus of a gene-targeted somatic cell have beenReproductive Biology and Endocrinology 2004, 2:40 http://www.rbej.com/content/2/1/40
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created using promoterless vectors [50,51,54,96]. Gene
targeting in human somatic cells is also conducted with
promoterless vectors [102,103]. One caveat with this
approach is that the gene to be targeted must be expressed
in the cells being used, as it is the promoter from the tar-
geted gene which will drive expression of the neomycin
resistance cassette. Fortunately, each of the three genes we
plan to disrupt are expressed in rhesus fibroblasts.
Not all gene targeting events result in functional disrup-
tion of the gene of interest. Given the expense and time
involved in creating rhesus macaques through nuclear
transfer, it is desirable to be as certain as possible that
functional disruption of a targeted gene has been achieved
prior to nuclear transfer. One advantage of targeting the
HPRT1 gene is that functional selection can be applied.
Specifically, only cells that do not express HPRT1 can sur-
vive selection with 6-thioguanine (6TG) [104]. Since
HPRT1 is located on chromosome X, transfection of a
HPRT1 targeting vector in XY cells will result in 6TG-resist-
ant cells only if the HPRT1 gene is functionally disrupted.
Any cells that continue to express functional HPRT1 after
transfection will be killed by 6TG. Thus, it will be possible
to produce cells that have been verified to have no HPRT1
function.
Other approaches may improve gene targeting in NHPs
still further. For example, allthough infrequently used, rel-
atively high levels of gene targeting have been achieved
with adenovirus vectors [105]. Gene targeting in somatic
cells has been recently shown to be dramatically
improved with two experimental protocols: 1. thymidine
block of cell replication and 2. including a SV40 enhancer
sequence in the targeting construct [106]. Thymidine
treatment has been shown to induce homologous, but not
nonhomologous, recombination [107]. A 72 bp fragment
from the SV40 enhancer improves import of plasmids
into cell nuclei [108]. This sequence apparently allows
plasmids to bind to transcription factors which are trans-
ported to the nucleus via nucleus localization signals
[108]. The combination of thymidine treatment and the
presence of the SV40 enhancer sequence in the targeting
construct allowed Mir and Piedrahita to obtain a ratio of
homologous recombination to random integration of the
construct of 1:3 after electroporating bovine fetal fibrob-
lasts [106]. It is notewothy that they achieved this phe-
nomenal gene targeting rate with a construct that did
contain a promoter driving expression of the selection
cassette.
Summary and future directions
The production of genetically modified rhesus macaques
poses a number of serious challenges. The first step is to
produce genetically modified cells (Table 1). We have
achieved random integration of a construct and stable
expression of GFP. The more difficult feat of gene target-
ing is expected to be greatly facilitated by extending the
lifespan of somatic cells with hTERT. Thymidine treat-
ment and improved nuclear import of targeting constructs
with SV40 enhancer sequence may also substantially
improve gene targeting in rhesus macaque somatic cells. A
number of rhesus ES cell lines have been derived. Some of
these may prove useful in gene targeting experiments. The
problems associated with nuclear transfer from somatic
cells are currently being tackled. Experience with rhesus
embryonic and human somatic cells suggests that there is
no unsolvable barrier to whole animal cloning in pri-
mates [109-112]. Solving the various challenges to pro-
ducing genetically modified macaques is well worth the
effort as null mutant NHPs will likely result in break-
through advances in the understanding of neurogenetic
disease and prove invaluable for preclinical trials of new
therapies.
References
1. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal
P, Agarwala R, Ainscough R, Alexandersson M, An P, Antonarakis SE,
Attwood J, Baertsch R, Bailey J, Barlow K, Beck S, Berry E, Birren B,
Bloom T, Bork P, Botcherby M, Bray N, Brent MR, Brown DG, Brown
SD, Bult C, Burton J, Butler J, Campbell RD, Carninci P, Cawley S,
Chiaromonte F, Chinwalla AT, Church DM, Clamp M, Clee C, Collins
FS, Cook LL, Copley RR, Coulson A, Couronne O, Cuff J, Curwen V,
Cutts T, Daly M, David R, Davies J, Delehaunty KD, Deri J, Dermitza-
kis ET, Dewey C, Dickens NJ, Diekhans M, Dodge S, Dubchak I, Dunn
DM, Eddy SR, Elnitski L, Emes RD, Eswara P, Eyras E, Felsenfeld A,
Fewell GA, Flicek P, Foley K, Frankel WN, Fulton LA, Fulton RS, Furey
TS, Gage D, Gibbs RA, Glusman G, Gnerre S, Goldman N, Goodstadt
L, Grafham D, Graves TA, Green ED, Gregory S, Guigo R, Guyer M,
Hardison RC, Haussler D, Hayashizaki Y, Hillier LW, Hinrichs A,
Hlavina W, Holzer T, Hsu F, Hua A, Hubbard T, Hunt A, Jackson I,
Jaffe DB, Johnson LS, Jones M, Jones TA, Joy A, Kamal M, Karlsson EK,
Karolchik D, Kasprzyk A, Kawai J, Keibler E, Kells C, Kent WJ, Kirby
A, Kolbe DL, Korf I, Kucherlapati RS, Kulbokas EJ, Kulp D, Landers T,
Leger JP, Leonard S, Letunic I, Levine R, Li J, Li M, Lloyd C, Lucas S,
Ma B, Maglott DR, Mardis ER, Matthews L, Mauceli E, Mayer JH,
McCarthy M, McCombie WR, McLaren S, McLay K, McPherson JD,
Meldrim J, Meredith B, Mesirov JP, Miller W, Miner TL, Mongin E,
Montgomery KT, Morgan M, Mott R, Mullikin JC, Muzny DM, Nash
WE, Nelson JO, Nhan MN, Nicol R, Ning Z, Nusbaum C, O'Connor
MJ, Okazaki Y, Oliver K, Overton-Larty E, Pachter L, Parra G, Pepin
KH, Peterson J, Pevzner P, Plumb R, Pohl CS, Poliakov A, Ponce TC,
Ponting CP, Potter S, Quail M, Reymond A, Roe BA, Roskin KM,
Rubin EM, Rust AG, Santos R, Sapojnikov V, Schultz B, Schultz J,
Schwartz MS, Schwartz S, Scott C, Seaman S, Searle S, Sharpe T,
Sheridan A, Shownkeen R, Sims S, Singer JB, Slater G, Smit A, Smith
Table 1: Procedural steps in producing a genetically modified 
rhesus macaque
1. Isolate isogenic genomic fragments using long and accurate 
PCR
2. Construct targeting construct
3. Transfect TERT life-span extended cells with targeting vector
4. Select and identify targeted clones
5. Remove TERT
6. Nuclear transfer
7. Embryo transfer
8. Analysis of genetically modified NHPReproductive Biology and Endocrinology 2004, 2:40 http://www.rbej.com/content/2/1/40
Page 6 of 8
(page number not for citation purposes)
DR, Spencer B, Stabenau A, Stange-Thomann N, Sugnet C, Suyama M,
Tesler G, Thompson J, Torrents D, Trevaskis E, Tromp J, Ucla C,
Ureta-Vidal A, Vinson JP, Von Niederhausern AC, Wade CM, Wall M,
Weber RJ, Weiss RB, Wendl MC, West AP, Wetterstrand K,
Wheeler R, Whelan S, Wierzbowski J, Willey D, Williams S, Wilson
RK, Winter E, Worley KC, Wyman D, Yang S, Yang SP, Zdobnov EM,
Zody MC, Lander ES: Initial sequencing and comparative anal-
ysis of the mouse genome. Nature 2002, 420:520-562.
2. Schwanzel-Fukuda M, Bick D, Pfaff DW: Luteininzing hormone-
releasing hormone (LHRH)-expressing cells do not migrate
normally in an inherited hypogonadal (Kallmann) syndrome.
Mol Brain Res 1989, 6:311-326.
3. Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R,
Carrozzo R, Maestrini E, Pieretti M, Taillon-Miller P, Brown CJ, Wil-
lard HF, Lawrence C, Persico MG, Camerino G, Ballabio A: A gene
deleted in Kallmann's syndrome shares homology with neu-
ral cell adhesion and axonal path-finding molecules. Nature
1991, 353:529-536.
4. Legouis R, Hardelin JP, Levilliers J, Claverie J-M, Compain S, Wunderle
V, Millasseau P, Le Paslier D, Cohen D, Caterina D, Bougueleret L,
Delemarre-Van de Waal H, Lutfalla G, Weissenbach J, Petit C: The
candidate gene for the X-linked Kallmann syndrome
encodes a protein related to adhesion molecules. Cell 1991,
67:423-435.
5. Bick D, Curry CJ, McGill JR, Schorderet DF, Bux RC, Moore CM:
Male infant with ichthyosis, Kallmann syndrome, chondrod-
ysplasia punctata, and an Xp chromosome deletion. Am J Med
Genet 1989, 33:100-107.
6. Ross MT, Ballabio A, Craig IW: Long-range physical mapping
around the human steroid sulfatase locus.  Genomics 1990,
6:528-539.
7. Petit C, Levilliers J, Weissenbach J: Long-range restriction map of
the terminal part of the short arm of the human X
chromosome. Proc Natl Acad Sci USA 1990, 87:3680-3684.
8. Johnson CL, Charmley P, Yen PH, Shapiro LJ: A multipoint linkage
map of the distal short arm of the human X chromosome.
Am J Hum Genet 1991, 49:261-266.
9. Incerti B, Guioli S, Pragliola A, Zanaria E, Borsani G, Tonlorenzi R,
Bardoni B, Franco B, Wheeler D, Ballabio A, et-al: Kallmann syn-
drome gene on the X and Y chromosomes: implications for
evolutionary divergence of human sex chromosomes.  Nat
Genet 1992, 2:311-314.
10. Gianfrancesco F, Sanges R, Esposito T, Tempesta S, Rao E, Rappold G,
Archidiacono N, Graves JA, Forabosco A, D'Urso M: Differential
divergence of three human pseudoautosomal genes and
their mouse homologs: implications for sex chromosome
evolution. Genome Res 2001, 11:2095-2100.
11. Ellison JW, Li X, Francke U, Shapiro LJ: Rapid evolution of human
pseudoautosomal genes and their mouse homologs. Mamm
Genome 1996, 7:25-30.
12. Nyhan WL: The recognition of Lesch-Nyhan syndrome as an
inborn error of purine metabolism. J Inherit Metab Dis 1997,
20:171-178.
13. Jinnah HA, De Gregorio L, Harris JC, Nyhan WL, O'Neill JP: The
spectrum of inherited mutations causing HPRT deficiency:
75 new cases and a review of 196 previously reported cases.
Mutat Res 2000, 463:309-326.
14. Engle SJ, Womer DE, Davies PM, Boivin G, Sahota A, Simmonds HA,
Stambrook PJ, Tischfield JA: HPRT-APRT-deficient mice are not
a model for lesch-nyhan syndrome.  Hum Mol Genet 1996,
5:1607-1610.
15. Thomas KR, Capecchi MR: Site-directed mutagenesis by gene
targeting in mouse embryo-derived stem cells.  Cell 1987,
51:503-512.
16. Doetschman T, Maeda N, Smithies O: Targeted mutation of the
Hprt gene in mouse embryonic stem cells. Proc Natl Acad Sci
1988, 85:8583-8587.
17. Gumy-Pause F, Wacker P, Sappino AP: ATM gene and lymphoid
malignancies. Leukemia 2004, 18:238-242.
18. Shiloh Y: ATM and related protein kinases: safeguarding
genome integrity. Nat Rev Cancer 2003, 3:155-168.
19. Crawford TO, Mandir AS, Lefton-Greif MA, Goodman SN, Goodman
BK, Sengul H, Lederman HM: Quantitative neurologic assess-
ment of ataxia-telangiectasia. Neurology 2000, 54:1505-1509.
20. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Sfez S,
Ashkenazi M, Pecker I, Frydman m., Harnik R, Patanjali SR, Simmons
A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers
NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins
FS, Shiloh Y: A single ataxia telangiectasia gene with a product
similar to PI-3 kinase. Science 1995, 268:1749-1753.
21. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F,
Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A: Atm-defi-
cient mice:  A paradigm of Ataxia telangiectasia. Cell 1996,
86:159-171.
22. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D:
Targeted disruption of ATM leads to growth retardation,
chromosomal fragmentation during meiosis, immune
defects, and thymic lymphoma. Genes Dev 1996, 10:2411-2422.
23. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, Campos-
Torres J, Leder P: Pleiotropic defects in ataxia-telangiectasia
protein-deficient mice.  Proc Natl Acad Sci, USA 1996,
93:13084-11389.
24. Davis S, Laroche S: What can rodent models tell us about cog-
nitive decline in Alzheimer's disease?  Mol Neurobiol 2003,
27:249-276.
25. Phinney AL, Horne P, Yang J, Janus C, Bergeron C, Westaway D:
Mouse models of Alzheimer's disease: the long and filamen-
tous road. Neurol Res 2003, 25:590-600.
26. Dodart JC, Mathis C, Bales KR, Paul SM: Does my mouse have
Alzheimer's disease? Genes Brain Behav 2002, 1:142-155.
27. Voytko ML, Tinkler GP: Cognitive function and its neural mech-
anisms in nonhuman primate models of aging, Alzheimer
disease, and menopause. Front Biosci 2004, 9:1899-1914.
28. Barr CS, Newman TK, Becker ML, Parker CC, Champoux M, Lesch
KP, Goldman D, Suomi SJ, Higley JD: The utility of the non-human
primate; model for studying gene by environment interac-
tions in behavioral research. Genes Brain Behav 2003, 2:336-340.
29. Tootell RB, Tsao D, Vanduffel W: Neuroimaging weighs in:
humans meet macaques in "primate" visual cortex. J Neurosci
2003, 23:3981-3989.
30. Stephenson J: Studies illuminate cause of fatal reaction in
gene-therapy trial. JAMA 2001, 285:2570.
31. Ye X, Mitchell M, Newman K, Batshaw ML: Prospects for prenatal
gene therapy in disorders causing mental retardation. Ment
Retard Dev Disabil Res Rev 2001, 7:65-72.
32. Zanjani ED, Anderson WF: Prospects for in utero human gene
therapy. Science 1999, 285:2084-2088.
33. Evans M, Hunter S: Source and nature of embryonic stem cells.
2002, 325:1003-1007.
34. Capecchi MR: Generating mice with targeted mutations. Nat
Med 2001, 7:1086-1090.
35. Doetschman TC: Gene targeting in embryonic stem cells. Bio-
technology 1991, 16:89-101.
36. Hooper ML: Embryonal Stem Cells.  Introducing Planned
Changes into the Animal Genome. Chur, Switzerland, Harwood
Academic; 1992. 
37. Hooper M, Hardy K, Handyside A, Hunter S, Monk M: HPRT-defi-
cient (Lesch-Nyhan) mouse embryos derived from germline
colonization by cultured cells. Nature 1987, 326:292-295.
38. Martin GR: Isolation of a pluripotent cell line from early
mouse embryos cultured in medium conditioned by terato-
carcinoma stem cells. Proc Natl Acad Sci U S A 1981, 78:7634-7638.
39. Evans MJ, Kaufman MH: Establishment in culture of pluripoten-
tial cells from mouse embryos. Nature 1981, 292:154-156.
40. Brinster RL: The effect of cells transferred into the mouse
blastocyst on subsequent development.  J Exp Med 1974,
140:1049-1056.
41. Mitalipov SM, Kuo HC, Hennebold JD, Wolf DP: Oct-4 expression
in pluripotent cells of the rhesus monkey. Biol Reprod 2003,
69:1785-1792.
42. Evans MJ, Notarieanni E, Laurie S, Moor RM: Derivation and pre-
liminary characterization of pluripotent cell lines from por-
cine and bovine blastocysts. Theriogenology 1990, 33:125-128.
43. Wheeler MB: Development and validation of swine embryonic
stem cells: a review. Reprod Fertil Dev 1994, 6:563-568.
44. Thomson JA, Marshall VS: Primate embryonic stem cells. Curr
Top Dev Biol 1998, 38:133-165.
45. Stranzinger GF: Embryonic stem-cell-like cell lines of the spe-
cies rat and Bovinae. Int J Exp Pathol 1996, 77:263-267.
46. Stice SL, Strelchenko NS, Keefer CL, Matthews L: Pluripotent
bovine embryonic cell lines direct embryonic development
following nuclear transfer. Biol Reprod 1996, 54:100-110.Reproductive Biology and Endocrinology 2004, 2:40 http://www.rbej.com/content/2/1/40
Page 7 of 8
(page number not for citation purposes)
47. Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Becker
RA, Hearn JP: Isolation of a primate embryonic stem cell line.
Proc Natl Acad Sci USA 1995, 92:7844-7848.
48. Hendrickx AG, Dukelow WR: Reproductive biology. Nonhuman
Primates in Biomedical Research: Biology and Management Edited by:
Bennett B T, Christian R A and Hendrickson R. San Diego, Academic
Press; 1995:147-191. 
49. Phelps CJ, Koike C, Vaught TD, Boone J, Wells KD, Chen SH, Ball S,
Specht SM, Polejaeva IA, Monahan JA, Jobst PM, Sharma SB, Lamborn
AE, Garst AS, Moore M, Demetris AJ, Rudert WA, Bottino R, Bertera
S, Trucco M, Starzl TE, Dai Y, Ayares DL: Production of alpha 1,3-
galactosyltransferase-deficient pigs. Science 2003, 299:411-414.
50. Dai Y, Vaught TD, Boone J, Chen SH, Phelps CJ, Ball S, Monahan JA,
Jobst PM, McCreath KJ, Lamborn AE, Cowell-Lucero JL, Wells KD,
Colman A, Polejaeva IA, Ayares DL: Targeted disruption of the
alpha1,3-galactosyltransferase gene in cloned pigs.  Nat
Biotechnol 2002, 20:251-255.
51. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im
GS, Samuel M, Bonk A, Rieke A, Day BN, Murphy CN, Carter DB,
Hawley RJ, Prather RS: Production of {alpha}-1,3-Galactosyl-
transferase Knockout Pigs by Nuclear Transfer Cloning. Sci-
ence 2002, epub ahead of print:.
52. Denning C, Burl S, Ainslie A, Bracken J, Dinnyes A, Fletcher J, King T,
Ritchie M, Ritchie WA, Rollo M, de Sousa P, Travers A, Wilmut I,
Clark AJ: Deletion of the alpha(1,3)galactosyl transferase
(GGTA1) gene and the prion protein (PrP) gene in sheep.
Nat Biotechnol 2001, 19:559-562.
53. McCreath KJ, Howcroft J, Campbell KHS, Colman A, Schnieke AJ,
Kind AJ: Production of gene-targeted sheep by nuclear trans-
fer from cultured somatic cells. Nature 2000, 405:1066-1069.
54. Denning C, Dickinson P, Burl S, Wylie D, Fletcher J, Clark AJ: Gene
targeting in primary fetal fibroblasts from sheep and pig.
Cloning Stem Cells 2001, 3:221-231.
55. MacColl G, Bouloux P, Quinton R: Kallmann syndrome: adhe-
sion, afferents, and anosmia. Neuron 2002, 34:675-678.
56. Becker-Catania SG, Gatti RA: Ataxia-telangiectasia. Adv Exp Med
Biol 2001, 495:191-198.
57. Crawford TO: Ataxia telangiectasia.  Sem Ped Neurol 1998,
5:287-294.
58. Perlman S, Becker-Catania S, Gatti RA: Ataxia-telangiectasia:
diagnosis and treatment. Semin Pediatr Neurol 2003, 10:173-182.
59. La Spada AR, Taylor JP: Polyglutamines placed into context.
Neuron 2003, 38:681-684.
60. Selkoe DJ: Amyloid beta-protein and the genetics of Alzhe-
imer's disease. J Biol Chem 1996, 271:18295-18298.
61. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A,
Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekhar-
appa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini
AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in
the alpha-synuclein gene identified in families with Parkin-
son's disease. Science 1997, 276:2045-2047.
62. Chan AW, Luetjens CM, Dominko T, Ramalho-Santos J, Simerly CR,
Hewitson L, Schatten G: Foreign DNA transmission by ICSI:
injection of spermatozoa bound with exogenous DNA
results in embryonic GFP expression and live rhesus monkey
births. Mol Hum Reprod 2000, 6:26-33.
63. Chan AWS, Chong KY, Martinovich C, Simerly C, Schatten G: Trans-
genic monkeys produced by retroviral gene transfer into
mature oocytes. Science 2001, 291:309-312.
64. Wolfgang MJ, Eisele SG, Browne MA, Schotzko ML, Garthwaite MA,
Durning M, Ramezani A, Hawley RG, Thomson JA, Golos TG: Rhe-
sus monkey placental transgene expression after lentiviral
gene transfer into preimplantation embryos. Proc Natl Acad Sci
U S A 2001, 98:10728-10732.
65. Wolfgang MJ, Marshall VS, Eisele SG, Schotzko ML, Thomson JA,
Golos TG: Efficient method for expressing transgenes in non-
human primate embryos using a stable episomal vector. Mol
Reprod Dev 2002, 62:69-73.
66. Bitner-Glindzicz M: Hereditary deafness and phenotyping in
humans. Br Med Bull 2002, 63:73-94.
67. Graw J: The genetic and molecular basis of congenital eye
defects. Nat Rev Genet 2003, 4:876-888.
68. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E,
Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vana-
core N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA,
Heutink P: Mutations in the DJ-1 gene associated with auto-
somal recessive early-onset parkinsonism.  Science 2003,
299:256-259.
69. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y,
Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the
parkin gene cause autosomal recessive juvenile
parkinsonism. Nature 1998, 392:605-608.
70. Houck JC, Sharma VK, Hayflick L: Functional failures of cultured
human diploid fibroblasts after continued population
doublings. Proc Soc Exp Biol Med 1971, 137:331-333.
71. Hayflick L: The limited in vitro lifetime of human diploid cell
strains. Exp Cell Res 1965, 37:614.
72. Williams SH, Sahota V, Palmai-Pallag T, Tebbutt SJ, Walker J, Harris
A: Evaluation of gene targeting by homologous recombina-
tion in ovine somatic cells. Mol Reprod Dev 2003, 66:115-125.
73. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bod-
nar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R,
Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB: Recon-
stitution of human telomerase with the template RNA com-
ponent hTR and the catalytic protein subunit hTRT. Nat Genet
1997, 17:498-502.
74. Keith WN, Bilsland A, Evans TR, Glasspool RM: Telomerase-
directed molecular therapeutics.  Expert Rev Mol Med 2002,
2002:1-25.
75. Counter CM: The roles of telomeres and telomerase in cell
life span. Mutat Res 1996, 366:45-63.
76. Harley CB, Vaziri H, Counter CM, Allsopp RC: The telomere
hypothesis of cellular aging. Exp Gerontol 1992, 27:375-382.
77. Allsopp RC, Harley CB: Evidence for a critical telomere length
in senescent human fibroblasts. Exp Cell Res 1995, 219:130-136.
78. Chang WL, Kirchoff V, Pari GS, Barry PA: Replication of rhesus
cytomegalovirus in life-expanded rhesus fibroblasts express-
ing human telomerase. J Virol Methods 2002, 104:135-146.
79. Yudoh K, Matsuno H, Nakazawa F, Katayama R, Kimura T: Reconsti-
tuting telomerase activity using the telomerase catalytic
subunit prevents the telomere shorting and replicative
senescence in human osteoblasts.  J Bone Miner Res 2001,
16:1453.
80. Steinert S, Shay JW, Wright WE: Transient expression of human
telomerase extends the life span of normal human
fibroblasts. Biochem Biophys Res Commun 2000, 273:1095-1098.
81. Ouellette MM, Liao M, Herbert BS, Johnson M, Holt SE, Liss HS, Shay
JW, Wright WE: Subsenescent telomere lengths in fibroblasts
immortalized by limiting amounts of telomerase. J Biol Chem
2000, 275:10072-10076.
82. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Har-
ley CB, Shay JW, Lichtsteiner S, Wright WE: Extension of life-span
by introduction of telomerase into normal human cells. Sci-
ence 1998, 279:349-352.
83. Vaziri H, Benchimol S: Reconstitution of telomerase activity in
normal human cells leads to elongation of telomeres and
extended replicative life span. Curr Biol 1998, 8:279-282.
84. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber
DA, Weinberg RA: Telomerase activity is restored in human
cells by ectopic expression of hTERT (hEST2), the catalytic
subunit of telomerase. Oncogene 1998, 16:1217-1222.
85. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, Bronstein
A, Chiu CP, Herron GS: Human endothelial cell life extension
by telomerase expression. J Biol Chem 1999, 274:26141-26148.
86. Steinert S, White DM, Zou Y, Shay JW, Wright WE: Telomere biol-
ogy and cellular aging in non-human primate cells. Exp Cell Res
2002, 272:146-152.
87. Kirchoff V, Wong S, St JS, Pari GS: Generation of a life-expanded
rhesus monkey fibroblast cell line for the growth of rhesus
rhadinovirus (RRV). Arch Virol 2002, 147:321-333.
88. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, White
MA, Wright WE, Shay JW: Absence of cancer-associated
changes in human fibroblasts immortalized with telomerase.
Nat Genet 1999, 21:115-118.
89. Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M, Beeche M,
Bodnar AG, Wahl GM, Tlsty TD, Chiu CP: Telomerase expres-
sion in human somatic cells does not induce changes associ-
ated with a transformed phenotype.  Nat Genet 1999,
21:111-114.
90. Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM,
Bjorkholm M, Teh BT, Nordenskjold M, Xu D: Molecular charac-
terization of human telomerase reverse transcriptase-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2004, 2:40 http://www.rbej.com/content/2/1/40
Page 8 of 8
(page number not for citation purposes)
immortalized human fibroblasts by gene expression profil-
ing: activation of the epiregulin gene.  Cancer Res 2003,
63:1743-1747.
91. Cui W, Wylie D, Aslam S, Dinnyes A, King T, Wilmut I, Clark AJ: Tel-
omerase-immortalized sheep fibroblasts can be repro-
grammed by nuclear transfer to undergo early
development. Biol Reprod 2003, 69:15-21.
92. te Riele H, Maandag ER, Berns A: Highly efficient gene targeting
in embryonic stem cells through homologous recombination
with isogenic DNA constructs. Proc Natl Acad Sci U S A 1992,
89:5128-5132.
93. Waldman AS, Liskay RM: Dependence of intrachromosomal
recombination in mammalian cells on uninterrupted
homology. Mol Cell Biol 1988, 8:5350-5357.
94. Sedivy JM, Vogelstein B, Liber HL, Hendrickson EA, Rosmarin A:
Gene targeting in human cells without isogenic DNA. Science
1999, 283:9a.
95. Hanson KD, Sedivy JM: Analysis of biological selections for high-
efficiency gene targeting. Mol Cell Biol 1995, 15:45-51.
96. Brown JP, Wei W, Sedivy JM: Bypass of senescence after disrup-
tion of p21CIP1/WAF1 gene in normal diploid human
fibroblasts. Science 1997, 277:831-834.
97. Vasquez KM, Marburger K, Intody Z, Wilson JH: Manipulating the
mammalian genome by homologous recombination. Proc Natl
Acad Sci U S A 2001, 98:8403-8410.
98. Zwaka TP, Thomson JA: Homologous recombination in human
embryonic stem cells. Nat Biotechnol 2003, 21:319-321.
99. Hasty P, Rivera-Perez J, Bradley A: The length of homology
required for gene targeting in embryonic stem cells. Mol Cell
Biol 1991, 11:5586-5591.
100. Schwartzberg PL, Robertson EJ, Goff SP: Targeted gene disrup-
tion of the endogenous c-abl locus by homologous recombi-
nation with DNA encoding a selectable fusion protein. Proc
Natl Acad Sci USA 1990, 87:3210-3214.
101. Jeannotte L, Ruiz JC, Robertson EJ: Low level of Hox1.3 gene
expression does not preclude the use of promoterless vec-
tors to generate a targeted gene disruption. Mol Cell Biol 1991,
11:5578-5585.
102. Sedivy JM, Sharp PA: Positive genetic selection for gene disrup-
tion in mammalian cells by homologous recombination. Proc
Natl Acad Sci USA 1989, 86:227-231.
103. Sedivy JM, Dutriaux A: Gene targeting and somatic cell genet-
ics:  a rebirth or a coming of age? Trends Genet 1999, 15:88-90.
104. Cox R, Masson WK: The isolation and preliminary characteri-
sation of 6-thioguanine-resistant mutants of human diploid
fibroblasts. Mutat Res 1976, 36:93-104.
105. Fujita A, Sakagami K, Kanegae Y, Saito I, Kobayashi I: Gene target-
ing with a replication-defective adenovirus vector. J Virol 1995,
69:6180-6190.
106. Mir B, Piedrahita JA: Nuclear localization signal and cell syn-
chrony enhance gene targeting efficiency in primary fetal
fibroblasts. Nucleic Acids Res 2004, 32:e25.
107. Lundin C, Erixon K, Arnaudeau C, Schultz N, Jenssen D, Meuth M,
Helleday T: Different roles for nonhomologous end joining and
homologous recombination following replication arrest in
mammalian cells. Mol Cell Biol 2002, 22:5869-5878.
108. Dean DA, Dean BS, Muller S, Smith LC: Sequence requirements
for plasmid nuclear import. Exp Cell Res 1999, 253:713-722.
109. Hwang WS, Ryu YJ, Park JH, Park ES, Lee EG, Koo JM, Chun HY, Lee
BC, Kang SK, Kim SJ, Ahn C, Hwang JH, Park KY, Cibelli JB, Moon SY:
Evidence of a Pluripotent Human Embryonic Stem Cell Line
Derived from a Cloned Blastocyst. Science 2004.
110. Mitalipov SM, Yeoman RR, Nusser KD, Wolf DP: Rhesus monkey
embryos produced by nuclear transfer from embryonic blas-
tomeres or somatic cells. Biol Reprod 2002, 66:1367-1373.
111. Wolf DP, Meng L, Ouhibi N, Zelinski-Wooten M: Nuclear transfer
in the Rhesus monkey:  Practical and basic implications. Biol
Reprod 1999, 60:199-204.
112. Meng L, Ely JJ, Stouffer RL, Wolf DP: Rhesus monkeys produced
by nuclear transfer. Biol Reprod 1997, 57:454-459.